CD19 and diffuse large B-cell lymphoma: More options in R/R disease include tafasitamab, a humanized, Fc-modified, CD-19-targeting monoclonal antibody that was approved in combination with lenalidomide in patients with R/R DLBCL based on the results of the L-MIND phase II trial [12].